IL132145A - Compositions for treating inflammatory bowel disease and uses thereof - Google Patents

Compositions for treating inflammatory bowel disease and uses thereof

Info

Publication number
IL132145A
IL132145A IL13214598A IL13214598A IL132145A IL 132145 A IL132145 A IL 132145A IL 13214598 A IL13214598 A IL 13214598A IL 13214598 A IL13214598 A IL 13214598A IL 132145 A IL132145 A IL 132145A
Authority
IL
Israel
Prior art keywords
compositions
inflammatory bowel
bowel disease
treating inflammatory
treating
Prior art date
Application number
IL13214598A
Other languages
English (en)
Other versions
IL132145A0 (en
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Publication of IL132145A0 publication Critical patent/IL132145A0/xx
Publication of IL132145A publication Critical patent/IL132145A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13214598A 1997-04-01 1998-04-01 Compositions for treating inflammatory bowel disease and uses thereof IL132145A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
IL132145A0 IL132145A0 (en) 2001-03-19
IL132145A true IL132145A (en) 2005-11-20

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13214598A IL132145A (en) 1997-04-01 1998-04-01 Compositions for treating inflammatory bowel disease and uses thereof

Country Status (16)

Country Link
US (1) US6277836B1 (OSRAM)
EP (1) EP0971735B1 (OSRAM)
JP (3) JP2001524951A (OSRAM)
AR (1) AR012304A1 (OSRAM)
AT (1) ATE389417T1 (OSRAM)
CA (1) CA2285923C (OSRAM)
CY (1) CY1109783T1 (OSRAM)
DE (1) DE69839261T2 (OSRAM)
DK (1) DK0971735T3 (OSRAM)
ES (1) ES2303351T3 (OSRAM)
IL (1) IL132145A (OSRAM)
NO (1) NO325947B1 (OSRAM)
NZ (1) NZ500696A (OSRAM)
PT (1) PT971735E (OSRAM)
SI (1) SI0971735T1 (OSRAM)
WO (1) WO1998043667A1 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20030099715A1 (en) * 2000-03-28 2003-05-29 Schwarz Franz Xaver Granulated particles with masked taste
CA2420576C (en) * 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003298937A1 (en) * 2002-12-06 2004-06-30 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
EP2586427A3 (en) * 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
EP2280713A1 (en) * 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
NZ598716A (en) 2009-10-26 2014-08-29 Borody Thomas J Novel enteric combination therapy
EP2563117B1 (en) 2010-04-26 2018-02-21 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
PL2651415T3 (pl) 2010-12-13 2021-04-19 Rite-Prep Pty Ltd. Formulacje dożołądkowe i dookrężnicze oraz sposoby ich wytwarzania i zastosowania
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
ES2842443T3 (es) 2016-02-26 2021-07-14 Debiopharm Int Sa Medicamento para el tratamiento de infecciones del pie diabético
IL285204B2 (en) 2019-02-14 2025-02-01 Debiopharm Int Sa Formulation of apavicin, method for its preparation
EP3982975A1 (en) 2019-06-14 2022-04-20 Debiopharm International SA Afabicin for use for treating bacterial infections involving biofilm
IL299287A (en) 2020-06-30 2023-02-01 Redhill Biopharma Ltd Fixed-dose triple antibiotic combination products, dosing regimen, methods, and kits for the treatment of pulmonary mycobacterial infections other than tuberculosis
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
WO1998043667A1 (en) 1998-10-08
EP0971735A1 (en) 2000-01-19
EP0971735B1 (en) 2008-03-19
SI0971735T1 (sl) 2008-08-31
CY1109783T1 (el) 2013-09-04
DE69839261D1 (de) 2008-04-30
US6277836B1 (en) 2001-08-21
DE69839261T2 (de) 2009-03-26
JP2008024713A (ja) 2008-02-07
IL132145A0 (en) 2001-03-19
NO325947B1 (no) 2008-08-25
EP0971735A4 (en) 2004-02-25
JP2001524951A (ja) 2001-12-04
AR012304A1 (es) 2000-10-18
ES2303351T3 (es) 2008-08-01
CA2285923C (en) 2013-03-12
NO994778L (no) 1999-11-30
PT971735E (pt) 2008-06-02
CA2285923A1 (en) 1998-10-08
NZ500696A (en) 2002-05-31
ATE389417T1 (de) 2008-04-15
JP2012126736A (ja) 2012-07-05
DK0971735T3 (da) 2008-07-07
NO994778D0 (no) 1999-09-30

Similar Documents

Publication Publication Date Title
IL132145A (en) Compositions for treating inflammatory bowel disease and uses thereof
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
ZA98454B (en) Personal cleansing compositions
EP0766564A4 (en) SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
IL127636A0 (en) Polyester compositions
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1020194A4 (en) AQUEOUS TYPE EMULSION COMPOSITIONS
HUP0103562A3 (en) Novel compositions and use
ZA98455B (en) Personal cleansing compositions
PL336349A1 (en) Compositions for and methods for treating and diagnosing the mastocarcinoma
GB9720797D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
AU6386499A (en) Method and composition for treatment of inflammatory bowel disease
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
GB9901577D0 (en) Polyester compositions
PL330353A1 (en) Detergent hair-care compositions and their application
IL120488A (en) Modifiers for water-setting inorganic compositions and modified water-setting inorganic compositions
HUP0400922A3 (en) Detergent compositions and their use
GB9824450D0 (en) Malodour counteractant compositions
ZA982645B (en) Methods and compositions for treating inflammatory bowel disease
PL342253A1 (en) Pharmacological compositions based on bibapticide for visualising and treating thrombuses
PL338379A1 (en) Novel photoinitiators and their application
GB9725346D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
GB9701041D0 (en) Treatment of inflammatory bowel conditions
AUPO978597A0 (en) Methods of treating inflammatory bowel disease
HUP0004274A3 (en) Bispyrido-cycloheptane compounds and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired